ERs could be key to boosting HPV shots in High-Risk adults
NCT ID NCT06229353
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study explored whether giving the HPV vaccine in the emergency department (ER) could help protect adults aged 18-45 who haven't been fully vaccinated. Researchers enrolled 34 participants and offered the vaccine during their ER visit, with follow-up doses at 2 and 6 months. The goal was to see if the ER is a practical place to reach high-risk, under-immunized adults and improve vaccination rates against HPV, which can cause certain cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HPV vaccine (Gardasil 9)
What this could lead to
If successful, this approach could make it easier for high-risk adults to get the HPV vaccine during an ER visit, potentially preventing HPV-related cancers.
What could go wrong
The study was terminated early with only 34 participants, so results are limited. It may not show a clear benefit or be practical in other ER settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294-0022, United States